SpyGlass Pharma develops an eye lens with drug pads that releases glaucoma medicine over time, for use during cataract surgery. SGP reports earnings on Thu, Nov 5, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 14 | Raymond James | Initiated | Buy |
Whale Options Flow
90DNo whale options trades in SGP in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SGP is in one of them and how their past SGP trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered SGP in an article yet. Here's the latest on the wider market.
About SpyGlass Pharma
SpyGlass Pharma is a biopharmaceutical company based in Irvine, California, that develops long lasting drug delivery products for people with chronic eye conditions. Its lead product candidate is an intraocular lens fitted with drug pads that releases bimatoprost, a medicine already approved for topical use, to lower eye pressure in patients with glaucoma or ocular hypertension. The lens is designed to be implanted during routine cataract surgery, so its main customers are cataract surgeons and the patients they treat. The product is still in clinical trials and is not yet approved for sale.
- Headquarters
- Irvine, CA